Join the 'Thrombocytopenia' group to help and get support from people like you.
Posted 20 Nov 2012 by Drugs.com
LONDON, Nov. 19, 2012 – GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Promacta for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. Promacta is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. Promacta in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure. There are limitations to the use of Promacta in patients suffering from chronic hepatitis C-associated thrombocytopenia. These include: Promacta should not be used in an attempt to normalize platelet counts; Promacta should be used only in patients with ch ... Read more
Ask a Question
Related Condition Support Groups
Related Drug Support Groups
prednisone, dexamethasone, Decadron, Deltasone, Sterapred, Sterapred DS, Liquid Pred, Adrenocot, Promacta, view more... eltrombopag, Cerezyme, Meticorten, Decaject, Dexpak Taperpak, Orasone, Prednicen-M, Medidex LA, Prednicot, Baycadron, Dalalone, Dexamethasone Intensol, Dexone, Dexacen-4, Solurex, Solurex LA, Decadron-LA, imiglucerase, Hexadrol, De-Sone LA, Dexacort-LA, Primethasone, Dexacorten, Dexone LA, Dexasone LA, Dexasone, Medidex